IPF 'Graveyard' Gets 1 More; Gilead Drops Work on Letairis
By Jennifer Boggs
Monday, December 27, 2010
With Gilead Sciences Inc. halting work on Letairis (ambrisentan) in idiopathic pulmonary fibrosis (IPF) after a peek at Phase III data showed a lack of efficacy, InterMune Inc.'s pirfenidone remains the last late-stage player standing in IPF, a disease for which there are no approved drugs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.